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L-DOPA-induced dyskinesias (LIDs) are one of the main motor side eﬀects of L-DOPA therapy in Parkinson’s disease. The review
will consider the biochemical evidence indicating that the serotonergic neurons are involved in the dopaminergic eﬀects of L-
DOPA in the brain. The consequences are an ectopic and aberrant release of dopamine that follows the serotonergic innervation
of the brain. After mid- to long-term treatment with L-DOPA, the pattern of L-DOPA-induced dopamine release is modiﬁed. In
several brain regions, its eﬀect is dramatically reduced while, in the striatum, its eﬀect is quite preserved. LIDs could appear when
the dopaminergic eﬀects of L-DOPA fall in brain areas such as the cortex, enhancing the subcortical impact of dopamine and
promoting aberrant motor responses. The consideration of the serotonergic system in the core mechanism of action of L-DOPA
opens an important reserve of possible strategies to limit LIDs.
1.Introduction
Parkinson’s disease is the second most devastating neu-
rodegenerative disease aﬀecting more than 6 million people
worldwide and whose prevalence is expected to double
within the next twenty years [1]. This neurological disorder
is characterized by the progressive loss of mesencephalic
dopaminergic (DA) neurons from the substantia nigra pars
compacta and associated with numerous motor symptoms
(bradykinesia, rigidity, and tremor) [2, 3]. L-DOPA, the pre-
cursorofDA,hasbeenintroducedinthemid60’sasamiracle
pill to prevent the motor symptoms [4, 5]. However, upon
chronic use of this medication, its eﬃcacy slowly decreases
leading to increase the doses of L-DOPA, which generate
numerous side eﬀects. After 5 to 10 years of L-DOPA
treatment, Parkinsonian patients develop dyskinesias [6],
which consist of stereotypical choreic or ballistic movements
involving mostly the head, trunk, and limbs [7]. These
abnormal involuntary movements are often more debilitat-
ing than the motor symptoms themselves.
Preclinical research has permitted validating animal
models to study the mechanisms of L-DOPA-induced dysk-
inesias (LIDs). The most commonly used rat model that
showsbestfaceandpredictivevalidity,hasbeendevelopedby
Cenci and collaborators [8, 9] by producing severe lesion of
the nigrostriatal DA pathway in adult rats with the unilateral
injection of 6-hydroxydopamine (6-OHDA) in the medial
forebrain bundle [10, 11]. A chronic treatment with L-
DOPA for 3 weeks at low therapeutic doses (6–10mg/kg)
induced axial, limb, and orolingual abnormal involuntary
movements (ALO AIMs) of variable occurrence and severity
in rats [9, 12]. Despite extensive research done to understand
how these motor complications develop in the Parkinsonian
brain, all hypotheses could not be fully validated and new
insights in this ﬁeld need to be pushed forward to further
gain in understanding of LIDs. In the present review, we
will focus on the literature showing a prominent role of
serotonergic neurons (5-HT) in the mechanisms of action
of L-DOPA and how these neurons may contribute to the
development of LIDs. Speciﬁcally, we will try to develop a
new hypothesis that LIDs appear when the eﬀect of L-DOPA
falls in brain areas such as the cortex, then enhancing the
subcortical impact of DA at the risk to elicit LIDs.2 Parkinson’s Disease
2. Mechanismof Action of L-DOPA in5-HT
Neurons andCollateralConsequences
It has long been thought that the therapeutic beneﬁt of L-
DOPA may depend on its ability to restore DA extracellular
levels in the striatum through spared DA neurons [13–
15]. However, contradictory data have shown that the fewer
DA neurons that are spared, the more pronounced is the
release of DA induced by L-DOPA [16–21]. Furthermore, L-
DOPA-induced DA release is not sensitive to DA autoregu-
latory processes (DA-D2 autoreceptor stimulation and DAT
blockade) [19]. Other monoaminergic cells [22, 23], namely
serotonergic (5-HT) neurons, that are able to convert L-
DOPA into DA, store and induce an exocytotic release of DA,
rather participate in the mechanism of action of L-DOPA
[24].
2.1. L-DOPA and 5-HT Neurons. 5-HT neurons express the
amino acid decarboxylase (AADC) that converts L-DOPA
into DA and the vesicular membrane transporter VMAT2
that packages DA into exocytosis vesicles [25–28]. In line
with these molecular features, 5-HT neurons have been
shown for several years to release the newly synthesized DA
from their cell bodies and terminals [25, 29, 30]. Indeed, 5-
HTneurons areresponsible forthe TTX-sensitive, reserpine-
sensitive, and DA drugs-insensitive release of DA induced
by L-DOPA. The lesion of 5-HT neurons by the selective
neurotoxin 5,7-DHT drastically reduces the increase in DA
extracellular levels induced by a wide range of L-DOPA
doses (3–100mg/kg) [31, 32]. This eﬀect is dependent on
the extent of 5-HT denervation [31], which excludes the
involvement of any other cellular system in the release of
DA induced by L-DOPA. Furthermore, L-DOPA-induced
DA release is sensitive to 5-HT autoregulatory mechanisms.
Both the stimulation of 5-HT1A autoreceptors by the 5-
HT1A agonist 8-OHDPAT [33] and the blockade of 5-HT
transporters (SERT) by the selective serotonergic reuptake
inhibitors (SSRI) ﬂuoxetine [34]o rc i t a l o p r a m[ 31]r e d u c e
the increase in L-DOPA-derived DA extracellular levels.
These eﬀects are thought to occur via the inhibition of 5-
HTneuronactivity[35–42].Accordingly,ithasbeenrecently
shown that high-frequency stimulation of the subthalamic
nucleus, a surgical approach in Parkinson’s disease able to
inhibit 5-HT neuronal ﬁring [43], also reduces L-DOPA-
induced DA release [44].
5-HT neurons send a widespread innervation from the
raphe nuclei to the entire forebrain including the striatum
[46, 47]. Beyond the increase in striatal DA extracellular
levels, L-DOPA also induces a massive rise in DA levels
in the prefrontal cortex (PFC), the substantia nigra pars
reticulata (SNr), and the hippocampus (HIPP) [31]. In all
brain regions, L-DOPA-induced DA release is sensitive to 5-
HT pharmacological manipulation and the lesion of 5-HT
neurons [31, 44, 48]. This ectopic release of DA induced
by L-DOPA via 5-HT neurons creates a new balance in DA
chemistry throughout the Parkinsonian brain (Figure 1)[ 24,
31]. In physiological conditions, basal DA concentrations
are more than 30 times higher in the striatum compared to
other brain regions, in line with the restricted innervation
of mesencephalic DA neurons to striatal territories [5, 49].
While DA extracellular levels are from 4.6 to 7.8fmol/uL,
they are barely detectable depending on experimental con-
ditions (below 0.2fmol/uL) in the PFC, SNr, and HIPP
although DA receptors are expressed [50]. In Parkinsonian
conditions, the dose of L-DOPA required to “restore” similar
DA concentrations in the DA-denervated striatum is about
12mg/kg while it increases about 10 to 25 times DA concen-
trationsinotherbrainregions(seeFigure 1).Interestingly,L-
DOPAat3mg/kgenhancesDAlevelstosimilaramounts(0.7
to 1.3fmol) in the PFC, SNr, HIPP, and striatum. Therefore,
huge amounts of DA can be released beyond the striatum
[51] and may impact on DA receptors throughout the
Parkinsonian brain. In keeping with the increased sensitivity
of DA receptors that develops after DA denervation [52–54],
such an imbalanced DA transmission between the striatum
and other brain regions may participate in the emergence
in both short-term beneﬁts and long-term side eﬀects of L-
DOPA treatment (see Section 4).
2.2. Chronic Impact of L-DOPA on DA Release Pattern in
the Entire Forebrain. The therapeutic eﬃcacy of L-DOPA
treatment decreases over time with the development of
numerous side eﬀects including L-DOPA-induced dyskine-
sias (LIDs). LIDs are thought to emerge as a consequence of
the dysregulated release of DA as a “false neurotransmitter”
from 5-HT neurons [12, 31, 33, 44, 48, 57–63]. Indeed, the
inhibition of L-DOPA-induced DA release by 5-HT1 autore-
ceptors stimulation [33, 48] and/or 5,7-DHT lesion [31, 32]
is associated with a marked reduction in LIDs [48, 61].
However, these mechanisms have been described mostly in
the striatum while other brain regions could be involved
in the development of LIDs [60, 64–69]. Furthermore, the
dose of L-DOPA used, even within the therapeutic range (3–
12mg/kg), represents a critical parameter to consider in the
understanding of LIDs [70].
The occurrence and severity of LIDs in animals treated
chronically with L-DOPA depend on numerous parameters,
that is, the dose of L-DOPA, the site of 6-OHDA injection,
the extent of DA lesion, and rat strain. About half of animals
treated chronically with 3mg/kg of L-DOPA develop LIDs.
At 6mg/kg, about 2/3 of the animals treated with L-DOPA
display severe LIDs. At 12mg/kg and above, almost all
animals develop LIDs [9]. One consistent result observed
after chronic L-DOPA treatment is that, whatever the dose,
basal DA extracellular levels remain barely detectable in all
brain regions. In our experimental conditions (12mg/kg for
10days),basalDAlevelswerebelowthedetectionlimitinthe
striatum, SNr, PFC, and HIPP (Figure 1)[ 45]. In another
study using a 14-day treatment with 6mg/kg L-DOPA, base-
line DA concentrations were reduced by 99% to 0.04fmol/µL
inthestriatumcomparedtointactanimals(4fmol/µL)with-
out changes in the SNr (0.1-0.2fmol/µL) [48]. One study
showed a slight increase in basal DA levels in the stria-
t u m( r e a c h i n ga b o u t0 . 6 f m o l / µL) by using a higher dose
(25mg/kg) of L-DOPA administered twice a day [81].
Dynamics in the increase in DA release after each L-
DOPA administration may, however, diﬀer regarding the
dose of L-DOPA used. Some authors have proposed thatParkinson’s Disease 3
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Figure 1: Serotonergicneuronsareresponsibleforanimbalance ofdopaminechemistrywithinbrainregionsintheParkinsonianbrainafter
acute and chronic L-DOPA treatment. Data taken from [31, 45].4 Parkinson’s Disease
LIDs may emerge as a consequence of abnormal ﬂuctuations
in synaptic DA levels induced by L-DOPA treatment in
dyskinetic animals [48, 58, 59, 61, 73]. Larger increases in
synaptic DA levels induced by L-DOPA have been proposed
to be responsible for the emergence of peak-dose dyskinesia
in PD patients [59]. Data obtained with a chronic L-DOPA
treatment at 6mg/kg have shown that the kinetics of DA
release are diﬀerent in animals developing LIDs or not [73].
Although a higher magnitude of DA release was observed
in the striatum and SNr of dyskinetic animals compared to
nondyskinetic animals [48], this has not been consistently
observed [73]. In a recent report, our data have provided
new evidence for reconsidering the mechanisms of L-DOPA
withintheParkinsonianbrainandtheputativeconsequences
in many side eﬀects including LIDs [45]. We showed that
after a chronic L-DOPA treatment at 12mg/kg for 10 days,
the reactivity of 5-HT neurons to an acute challenge at 3
or 12mg/kg of L-DOPA was modiﬁed and resulted in a
potent loss of eﬃcacy of L-DOPA to increase DA release
(Figure 1). Most importantly, our data could depict a new
imbalance created by chronic L-DOPA treatment within the
striatum and other brain regions. The capacity of 5-HT
neurons to increase DA release in the SNr, HIPP, and PFC
was drastically reduced (about 70 to 90%) while it was less
aﬀected in the striatum. Indeed, the increase in striatal DA
release induced by 3mg/kg of L-DOPA after a 12mg/kg
treatment for 10 days was similar to that induced by an
acuteadministration of 3mg/kg. At12mg/kg, the eﬀectofL-
DOPA was reduced by only 50% after chronic compared to
acutetr eatment.I tappearsthatdiﬀerentmechanismsmaybe
processed in the striatum compared to other brain structures
that may account for the relatively preserved striatal DA
eﬀectofL-DOPA.Someofthesemechanismsmaybedirectly
related to the speciﬁc features and heterogeneity of 5-
HT terminals within brain regions. The resulted imbalance
between cortical versus subcortical brain regions in DA
transmission may potentially participate in development of
LIDs.
The following paragraph corresponds to the description
oftheFigure 1,(a)inphysiologicalconditions,dopaminergic
neurons originating from the substantia nigra pars compacta
(SNc) densely innervate the striatum (STR) where basal
dopamine (DA) concentrations range between 4.6 and
7.8nM. In the prefrontal cortex (PFC), the hippocampus
(HIPP), and the substantia nigra pars reticulata (SNr), basal
DA concentrations are much lower (<0.2nM). All these
brain regions express DA receptors and are innervated by
serotonergic neurons that originate from the dorsal and
medial raphe nuclei (DR/MR). (b) In Parkinsonian condi-
tions (i.e., unilateral 6-hydroxydopamine lesion in rats, 6-
OHDA rats), the neurodegeneration of DA neurons leads to
undetectable levels of DA in any brain region examined. (c)
In the absence of DA neurons, L-DOPA is decarboxylated
into DA, stored into exocytosis vesicles, and released in
the extracellular space by serotonergic neurons. In such
physiopathological condition, an acute administration of L-
DOPA at the low therapeutic dose of 3mg/kg induces a
homogeneous increase in DA concentrations in all brain
regions (see values in the square box). These concentrations
are2,2.5,and5timeshigherthaninphysiologicalconditions
in the SNr, PFC, and HIPP, respectively, while they are
5 times lower in the STR. (d) An acute administration
of L-DOPA at the moderate therapeutic dose of 12mg/kg
increases DA concentrations in the STR within the range
of physiological values. Similar concentrations of DA are
observed in the SNr and corresponded to >25 times the
physiological concentrations. In the PFC and HIPP, DA
concentrations are >10 times higher than in physiological
conditions. (e) After a chronic L-DOPA treatment at a
dose known to induce dyskinesias in all 6-OHDA rats
(12mg/kg/day for 10 days), basal DA concentrations remain
belowthedetectionlimitinallbrainregions.Allbiochemical
5-HT indexes (extracellular and tissue levels of 5-HT and
its metabolite 5-HIAA) are decreased after chronic L-DOPA
treatment, suggesting that 5-HT neurons suﬀer from chronic
exposure to L-DOPA. Numerous data provide evidence for
a 5-HT sprouting occurring speciﬁcally in the striatum [55,
56].(f)AfterachronicL-DOPAtreatment(12mg/kg/dayfor
10 days), a subsequent administration of 3mg/kg L-DOPA is
lesseﬃcienttoincreaseDAreleaseintheSNr,PFC,andHIPP
compared to an acute administration of the same dose in L-
DOPA-na¨ ıve 6-OHDA rats (see (c)). The ability of L-DOPA
toincreaseDAlevelsisreducedby43%,68%,and45%inthe
SNr, PFC, and HIPP, respectively. However, the eﬃcacy of L-
DOPA is not altered in the STR as DA levels reached similar
concentrations in both L-DOPA-treated and L-DOPA-na¨ ıve
6-OHDA rats. (g) The ability of L-DOPA at 12mg/kg to
increase DA release is diminished in all brain regions after
chronic L-DOPA treatment (12mg/kg/day for 10 days). The
highest loss of eﬃcacy is observed in the SNr (−92%), then
intheHIPP(−79%)andthePFC(62%).Bycomparison,the
eﬃcacy of L-DOPA remained mostly preserved in the STR
(−50%), an eﬀect that may be related to the striatal 5-HT
hyperinnervation [55].
3.Changes in5-HTTransmissionAssociated
with L-DOPA Treatment
L-DOPA, by entering 5-HT neurons, mediates numerous
changes in 5-HT neuron homeostasis [45]. The production
of massive amounts of DA has tremendous impact on 5-
HT function at the level of the metabolism, the activity, and
the morphology of 5-HT neurons (Table 1). Changes in 5-
HT indexes have been associated with the emergence of LIDs
(Table 2). Such changes may represent critical indicators of
the physiopathological state of the Parkinsonian brain that
should be taken into consideration to better control 5-HT
transmission and L-DOPA’s side eﬀects [24, 82, 83].
3.1. Impact of L-DOPA on 5-HT Transmission. Since the
beginning of the 70’s, numerous evidences started accumu-
latingforanalterationof5-HTneuronactivityinresponseto
L-DOPA (Table 1)[ 86–88]. The ﬁrst report in 1970 by Ng et
al. [25] showed that L-DOPA-enhanced [3H]-5-HT release
from [3H]-5-HT preloaded midbrain slices. This increase
in 5-HT release has been later conﬁrmed in vivo by local
administration of L-DOPA in the substantia nigra [71, 89].Parkinson’s Disease 5
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Table 2: Changes in biochemical, morphological, and molecular 5-HT indexes in dyskinetic (LID) versus nondyskinetic (LND) animals:
correlation with dyskinesias (R).
Animal model L-DOPA treatment Biochemical 5-HT indexes LID versus LND (R) Reference
6-OHDA rats 6mg/kg/d ip 14d tiss 5-HT: STR and CX LID > LND
R = 0.73 in CX [84]
6-OHDA rats 12mg/kg/d sc 5d tiss 5-HT (5,7-DHT): STR R = 0.713 [85]
6-OHDA rats 6mg/kg/d sc 14d ext and tiss 5-HT and
5-HIAA: STR and SNr LID > LND in STR [48]
6-OHDA rats 6mg/kg/d ip 21d tiss 5-HT: STR LID > LND
R = −0.655 [72]
Animal model L-DOPA treatment Morphological 5-HT
indexes LID versus LND (R) Reference
6-OHDA rats 5mg/kg/d ip 14d SERT immunoreactivity:
STR LID > LND [73]
6-OHDA rats 6mg/kg/d ip 21d 5-HT immunoreactivity
and AADC levels: STR LID > LND [74]
6-OHDA rats 6 and 50mg/kg/d ip
14–21d
SERT-binding density:
STR and CX
LID > LND, R = 0.796
in STR [55]
MPTP monkeys Modopar (4:1)
15–20mg/kg po 6–8m
SERT-binding density:
PUT and GP LID > LND in PUT [55]
Animal model L-DOPA treatment Molecular 5-HT indexes LID versus LND (R) Reference
MPTP monkeys Prolopa 100/25mg/kg
po1m
5-HT2AR-binding: STR
and PFC
LID > LND in DM
Caud and anterior
cingulate gyrus
[78]
6-OHDA: 6-hydroxydopamine; MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; ip: intraperitoneal; sc: subcutaneous; po: oral; d: day; m: month; tiss:
tissue; ext: extracellular; 5-HT: serotonin; 5-HIAA: 5-hydroxyindolacetic acid; 5,7-DHT: 5,7-dihydroxytryptamine; AADC: amino acid decarboxylase; SERT:
serotonergic transporter; 5-HT2AR: serotonin 2A receptor; STR: striatum; CX: cortex; SNr: substantia nigra pars reticulata; PUT: putamen; PFC: prefrontal
cortex;GP:globus pallidus;DMCaud:dorsomedialcaudatenucleus;LID:L-DOPA-treated dyskineticanimals;LND:L-DOPA-treatednondyskineticanimals;
R: correlation.
The potent increase in 5-HT levels observed in these studies
has been suggested to account for a nonexocytotic eﬄux of
5-HT via 5-HT transporters due to the strong displacement
of 5-HT from exocytosis vesicles by the newly synthesized
DA [24].However,recentdatausingsystemicadministration
of L-DOPA at moderate doses (3–12mg/kg) have reported
distinct eﬀects on 5-HT release depending on the dose and
the brain region dialysated. While an acute injection of
12mg/kg L-DOPA decreases 5-HT extracellular levels in the
PFC and SNr, a biphasic eﬀect was observed in the HIPP and
no eﬀect in the striatum [44, 45]. A transient increase in 5-
HT levels has been observed only after the very high dose of
100mg/kg in all brain regions (Navailles et al., unpublished
observation; see Table 1). Diﬀerent mechanisms could be
triggered regarding the dose of L-DOPA used (exocytotic
versus nonexocytotic) while the region-dependent eﬀects of
L-DOPA on 5-HT release may reﬂect the anatomo-func-
tional heterogeneity of 5-HT terminals [24].
After a chronic L-DOPA treatment (12mg/kg/day for
10 days), the reactivity of 5-HT terminals to a subsequent
challenge of L-DOPA (3–12mg/gk) was further modiﬁed in
a region-dependent manner [45]. The inhibitory eﬀect of L-
DOPA at 3 and 12mg/kg on 5-HT release was potentiated
in the SNr and HIPP of L-DOPA-treated rats but not in
the PFC. In the striatum of L-DOPA-treated rats, 5-HT
release remained unaltered by L-DOPA whatever the dose
used. Interestingly, this region-dependent reactivity of 5-HT
terminals appears to correlate with the ability of L-DOPA to
increase DA release after a chronic treatment (see Section 2).
Of particular interest, the lack of sensitivity of striatal 5-
HT terminals to L-DOPA on 5-HT release is associated
with a preserved increase in L-DOPA-induced DA release
while the highest sensitivity of 5-HT terminals observed
in the SNr leads to the most profound loss of eﬃcacy of
L-DOPAtoincreaseDArelease[45].Thisimbalancebetween
the striatum and the SNr could not be unmasked after
a chronic treatment with L-DOPA at 6mg/kg, which did
not change the eﬀect of L-DOPA on 5-HT release [48].
Nevertheless, it appears that, for a moderate though ther-
apeutic dose of L-DOPA (12mg/kg), its eﬀects on DA
transmission occur in detriment of 5-HT transmission [45].
The distinct molecular (variable expression and sensitivity to
5-HT1A/1B receptors, SERT, VGLUT3, cation channels) [90–
97], anatomical (originating from the medial or dorsal raphe
nuclei) [46, 98], ontogenesis (pet1-dependent versus pet1-
resistant 5-HT neurons) [99, 100] characteristics of 5-HT
neurons projecting to these diﬀerent brain regions may
participate in this region-dependent changes in 5-HT and
DA releases [24]. In addition, chronic L-DOPA treatment
by itself also alters the morphology of these 5-HT neurons
and the synaptic plasticity in various brain regions (Table 1)
[55, 56, 101–104], an eﬀect that may participate in the8 Parkinson’s Disease
imbalanced 5-HT and DA transmissions within structures
in the Parkinsonian brain and favor the onset of LIDs (see
below).
Beyond the changes of 5-HT release (Table 1), chronic
L-DOPA also alters 5-HT transmission by modifying the
expression and function of numerous 5-HT receptors. Stud-
ies that aimed at improving L-DOPA’s eﬀects have focused
on 5-HT1A/1B receptors. Although a decrease in 5-HT1A
receptor expression in the dorsal raphe (and hippocampus)
[105, 106] may be directly linked to the loss of 5-HT neurons
in Parkinsonian patients [107–111], an increase has been
described in the neocortex of Parkinson’s disease patients
[112],theputamen[105],caudatenucleus,andmiddlelayers
of premotor-motor cortices of MPTP-treated monkeys [77].
Although it remains diﬃcult to attribute these eﬀects to
the progression of the disease or to L-DOPA therapy in
Parkinsonian patients [107, 113], a massive increase in 5-
HT1A receptor binding could be observed in the caudate
nucleus of L-DOPA-treated MPTP-lesioned monkeys [77].
No alteration in 5-HT1B binding has been observed in
the striatum and substantia nigra of Parkinsonian patients
[114] and 6-OHDA rats [115] while an increase in 5-HT1B
receptor expression in these brain regions has been reported
after chronic L-DOPA treatment in 6-OHDA-lesioned rats
[75]. Other 5-HT receptors such as 5-HT2A and 5-HT2C
receptors have been proposed to improve L-DOPA therapy
in Parkinson’s disease [69, 79, 116–119]. These receptors
are known to be sensitive to chronic alteration of DA
transmission [119–122]. However, the few data available
havereportedconﬂictingresults.5-HT2A receptorexpression
has been shown to increase in the striatum of 6-OHDA rats
[76] and the neocortex of Parkinsonian patients [112] while
it did not change in the putamen and PFC of MPTP-treated
monkeys[78].AlthoughL-DOPAreversedtheincreaseinthe
striatum of 6-OHDA rats [76], it increased 5-HT2A receptor
bindinginthedorsomedialcaudatenucleusofMPTP-treated
monkeys [78]. 5-HT2C receptor expression was decreased in
the striatum but not in the subthalamic nucleus of 6-OHDA
rats without any change after L-DOPA treatment [76].
However,theincreasedexpressionof5-HT2C receptorsinthe
substantia nigra pars reticulata in Parkinsonian patients [80]
appears to participate in the overactivity of this brain region
by dampening the antiparkinsonian action of DA drugs in
6-OHDA rats primed with L-DOPA [120, 121]. Altogether,
these data indicate that chronic L-DOPA treatment alters 5-
HT function and the resulted changes in 5-HT markers have
been mostly associated with the genesis and expression of
LIDs.
3.2. Biochemical, Morphological, and Molecular Changes in 5-
HT Indexes Associated with LIDs. Changes in 5-HT indexes
have recently gained growing importance as they may reﬂect
ﬂuctuations in L-DOPA-induced DA release from 5-HT
neurons that have been associated with the emergence of
LIDs (Table 2)[ 61, 62]. In this attempt, most studies have
focused on modiﬁcations of tissue and extracellular levels of
5-HT together with changes in 5-HT terminals density and
morphology in 6-OHDA rats developing or not dyskinesias
after a chronic treatment with 6mg/kg of L-DOPA. Con-
ﬂicting results,however, haveemergedregarding 5-HT tissue
and extracellular levels. Independently of the emergence of
LIDs, chronic L-DOPAtreatmenteither reduced [45,48, 61],
did not aﬀect [72, 78], or tended to increase [84] 5-HT
tissueandextracellularlevelsinthestriatum.Inmoststudies,
however, tissue and extracellular 5-HT levels in the striatum
and the cortex, but not the SNr, of rats developing LIDs were
signiﬁcantly higher than in nondyskinetic rats [48, 72, 84]
suggesting a positive correlation to LIDs. Accordingly, Eskow
et al. [85], by using selective 5,7-DHT lesions that are known
to abolish both LIDs [61] and L-DOPA-induced DA release
[31], could establish a positive correlation between striatal 5-
HT levels and LIDs. These results are in contrast with the
study by Gil et al. [72] in which 5-HT tissue levels were
negatively correlated to axial, limb, and orolingual abnormal
involuntary movements (AIMs). Interestingly, Carta et al.
[84] could not establish a link between striatal 5-HT levels
but did observe a positive correlation between 5-HT levels
in the PFC and AIMs providing further evidence for a role
of 5-HT function beyond the striatum in the emergence of
LIDs.
In support of an increased 5-HT function in the gen-
esis of LIDs, chronic L-DOPA treatment has been shown
to increase AADC protein expression without increasing
tyrosine hydroxylase expression in the lesioned-side striatum
of dyskinetic rats [74]. This eﬀect was associated with a
higher 5-HT immunoreactivity compared to nondyskinetic
animals, highlighting an increased 5-HT ﬁber density medi-
ated by L-DOPA [74]. In line with this, Rylander et al. [55]
have shown that chronic L-DOPA induced a dose-dependent
increase in SERT-binding densities on the lesioned striatum
(and motor-premotor cortices) that was associated with an
increased number of striatal 5-HT varicosities but not with
an increase in the number of 5-HT cell bodies or expression
of SERT mRNA in raphe cells. Both striatal SERT binding
and number of 5-HT varicosities correlated positively with
the AIMs scores, showing that L-DOPA induced a sprout-
ing of striatal 5-HT terminals in dyskinetic animals [55].
Furthermore, SERT-immunoreactive varicosities displayed
larger synaptic incidence with striatal neurons and resulted
inlargeramountofstimulated(KClevoked)[3H]-DArelease
in striatal slices from L-DOPA-treated dyskinetic rats [55].
However, Lundblad et al. [73] failed to correlate the higher
5-HT nerve density in the lesioned striatum of dyskinetic
rats with the magnitude of KCl-evoked DA release mea-
sured in vivo by chronoamperometry after chronic L-DOPA
treatment. Although SERT binding was decreased in the
putamen and globus pallidus (GP) of MPTP-treated mon-
keys [55], a marked hyperinnervation of TPH-positive ﬁbers
(increase in number and diameter of TPH-positive axon
varicosities) was observed in the dorsal caudate and puta-
men, but not the GP of MPTP-intoxicated monkeys [56].
Nevertheless, using both 5-HT markers, these studies have
consistently shown an elevated SERT binding and a further
increase in the number and enlargement of TPH positive
axonal varicosities in caudate nucleus and putamen of
MPTP-treated monkeys that develop LIDs [55, 56]. In
Parkinsonian patients, SERT-binding levels were also signiﬁ-
cantly increased in both the putamen and GP of dyskineticParkinson’s Disease 9
patients [55]. Regarding the lifetime L-DOPA medication,
results indicate that patients with highest levels of SERT
binding were those developing LIDs earliest during their
PD treatment [55]. However, by using another marker of
serotonin transporter (11C-DASP) in PET, Politis et al.
[123] could not establish a correlation between 11C-DASP
binding and exposure to dopaminergic therapy. Altogether,
these data suggest that L-DOPA pharmacotherapy induced
a maladaptive plasticity of 5-HT axon terminals that may
predispose to LIDs. Indeed, the 5-HT hyperinnervation
together with marked hypertrophy of 5-HT axon varicosities
may worsen the ﬂuctuations of L-DOPA-induced DA release
[48, 55, 56, 59].
The combination of 5-HT1A and 5-HT1B agonists pro-
vides useful pharmacological manipulation to reduce the
large increases in DA eﬄux and the occurrence of LIDs
[48, 61, 124]. Their eﬃcacy is reached when combining
subthreshold doses of 5-HT1A and 5-HT1B agonists that are
thoughttoactivatepresynaptic5-HT1 receptorsanddampen
the release of L-DOPA-derived DA from 5-HT neurons [64].
The stimulation of postsynaptic 5-HT1 receptors on non-5-
HTneuronsmayalsocontributetotheirantidyskineticeﬀect
by modulating GABA and glutamate release [64]. However,
adverse eﬀects involving the stimulation of postsynaptic 5-
HT1A receptors could worsen their therapeutic eﬃcacy [125,
126]. Some studies have identiﬁed speciﬁc changes induced
by chronic L-DOPA treatment on 5-HT1B postsynaptic
receptors that may be directly involved in the development
of LIDs. Chronic L-DOPA treatment increased the expres-
sion of 5-HT1B receptors and its adaptor protein p11 at
striatonigral neurons [75]. The ability of 5-HT1B agonist
to reduce LIDs was p11 dependent [75]. Moreover, in L-
DOPA-treated 6-OHDA rats that recovered from AIMs after
a chronic treatment with citalopram (a selective serotonergic
reuptake inhibitor, SSRI),theexpression of 5-HT1B receptors
in the striatum was almost fullyabolished [127]. The authors
could reveal a positive correlation between the decreased
anxiety induced by citalopram and its ability to reduce
AIMs that involves a marked reduction in 5-HT1B receptor
expression(Table 2).However,inkeepingwithdataobtained
in the study by Zhang et al. [75], the reduction of LIDs
by citalopram may not solely account for its eﬀect on 5-
HT1B receptor expression but may also involve the ability
of citalopram to abolish L-DOPA-induced DA release [31].
Nevertheless, these data allow identifying a new association
between 5-HT1B r e c e p t o r sa n dL I D s .Ar e c e n tw o r kc o u l d
also highlight a relationship between 5-HT2A receptors and
LIDs in MPTP-treated monkeys [78]. [3H]Ketanserin-
speciﬁc binding to 5-HT2A receptors was increased in the
dorsomedial caudate nucleus and anterior cingulated gyrus
of dyskinetic L-DOPA-treated MPTP-intoxicated monkeys,
an eﬀect reversed by drugs inhibiting the expression of LIDs.
The authors could reveal a positive correlation between the
maximal dyskinesia scores at the end of L-DOPA treatment
and 5-HT2A receptor-speciﬁc binding in the anterior and
posterior caudate nucleus as well as the nucleus accumbens
[78].
Despite the high degree of variability observed in the
changes of 5-HT markers across studies performed in diﬀer-
ent animal models and Parkinsonian patients, the available
data to date allow establishing a clear role of the 5-HT system
in the induction and maintenance of LIDs. The numerous
5-HT indexes used could provide interesting insights into
the mechanisms of action of L-DOPA in mediating LIDs.
However, the failure to fully correlate one change in 5-
HT markers with a complex behavior such as LIDs may
encourage future studies to reconsider the heterogeneity and
the widespread inﬂuence of the 5-HT system as a whole fun-
damental index in the genesis of LIDs. Indeed, the numerous
changes in 5-HT function induced by L-DOPA in multiple
brain regions may concur in synergy to an imbalanced DA
transmission that may participate in the emergence of LIDs.
4. Functional Outcomes of
5-HTNeuron-MediatedDA
TransmissioninLIDs
Because the 5-HT terminals are responsible for the gross
increaseinDA,leadingtoahomogeneousandectopicrelease
of DA in the brain, one may wonder the extent to which the
striatum is involved in the therapeutic beneﬁt of L-DOPA. It
is far from our purpose to rule out many years of research
centred on striatal DA transmission, but it is important to
conceive that other brain regions play an important role in
motor responses induced by L-DOPA. The main argument
to look beyond the striatum is the success of the deep
brain stimulation of the subthalamic nucleus in Parkinson
patients, a surgical approach of the disease that does not rely
on striatal DA release.
4.1. Role of Imbalanced Cortical-Subcortical DA Transmission
in Motor Output. It is a common sense to reaﬃrm that
DA transmission is altered in PD and that the relation-
ships between DA transmission, symptoms severity, and
medication coevolve with the deleterious progression of the
disease. Nonetheless, adding the evidence that 5-HT neurons
participate in the raise of extracellular DA oﬀers a larger
picture of the putative scenarios. In early stages of the
disease, the presence of spared DA terminals and DAT in
the striatum limits the excessive increase in DA extracellular
levels induced by L-DOPA from 5-HT neurons. However,
the increase in DA from 5-HT terminals in the striatum
likely introduces a noise in the “coherent” DA transmission.
Indeed, this aberrant release is not regulated while the
“coherent” release from spared DA neurons is impaired
due to the inhibitory eﬀect of electrical activity of L-DOPA
on DA neurons activity [19]. The more the disease pro-
gresses, the higher should be the contribution of 5-HT
neurons in L-DOPA-induced DA release. Thus, even in the
early stages of the disease, it is noticeable that L-DOPA is
eﬃcient to treat the core symptoms of the disease (tremor,
bradykinesia, rigidity, posture) but has limited eﬀects on
precise coordinated movements or some impaired cognitive
functions [128]. In the advanced stages of the disease, spared
DA neurons are no longer able to buﬀer excessive swings of10 Parkinson’s Disease
DA released from 5-HT neurons, a condition favoring motor
ﬂuctuations and LIDs [61].
Whatever the stage of the disease, the small release of DA
from 5-HT neurons has potentially a larger impact beyond
the striatum where DAT are poorly expressed. The impact
may also be magniﬁed due to altered pattern of activities
found in extrastriatal territories such as the cortex or the
HIPP. Indeed, numerous studies in humans using functional
imaging have reported changes in activities in several
cortical territories and the HIPP [129]. These brain areas
expressing substantial amount of DA receptors [50], the
excessive increase in DA release induced by L-DOPA in
these territories could have a higher impact on the functions
exerted by these brain regions. Of note, it has been described
formanyyearsthatanincreaseincorticalDAmaycounteract
aberrant DA signaling in subcortical areas. For instance, the
catalepsy induced by the DA antagonist haloperidol, a rat
model of Parkinsonism, is reversed by the direct infusion
of DA into the PFC. Moreover, the increase in DA release
induced by L-DOPA is very high in the SN, one of the brain
regions receiving the strongest 5-HT innervation [46], and
it has been shown for several years that the SN directly
participates in the motor eﬀects of L-DOPA in the 6-OHDA
rat model of Parkinson’s disease [68, 130].
TheminimalreleaseofstriatalDAaftertherapeuticdoses
ofL-DOPAcouldbecompensatedbyanincreaseinD2 recep-
tor eﬃciency. An increase in striatal D2 receptors has been
reported in early stages of the disease, but some data have
reported that DA “replacement” therapy reduced the exces-
sive expression of striatal D2 r e c e p t o r st ol e v e l sc o m p a r a b l e
to matched controls [131, 132]. Based on the neurochemical
data in the 6-OHDA rat model of Parkinson’s disease,
the beneﬁt of L-DOPA could be an uneven release of DA
or a hypodopaminergy in the striatum combined with an
extrastriatal hyperdopaminergy.
4.2. Role of Imbalanced Cortical-Subcortical DA Transmission
in LIDs. The increase in DA release induced by L-DOPA
has been directly incriminated in LIDs [133]. Our data
showing that chronic treatment with L-DOPA is associated
w i t had r a m a t i cl o s so fD Ar e l e a s ei nv a r i o u sr a tb r a i na r e a s
compared to the striatum [45] points to an inverse schema.
First, the inhibitory tone provided by cortical DA upon sub-
cortical DA function would be lowered after chronic treat-
ment, and subcortical DA release by 5-HT ﬁbers would be
preserved due to some sprouting of striatal 5-HT ﬁbers
[55, 56]. The situation is not known for several brain
regions though it has been reported that LIDs in rodents
is associated with an increase in c-Fos expression in the
STN [134]. Besides, chronic L-DOPA treatment has been
shown to increase c-Fos expression also in the cortex and
globus pallidus [135, 136]. In addition, excessive DA tone
in some brain regions other than the striatum may promote
abnormal involuntary movement of the face, one clinical
manifestation reported in LIDs in primates and rodents [7–
9]. Second, the aberrant release of DA via 5-HT neurons
would favor abnormal learning, at least in the striatum.
Indeed, DA is critically involved in procedural learning, and
LIDs is thought to result in part from aberrant molecular
events at the level of medium spiny neurons of the striatum
that involve DA receptors [104, 137, 138]. The postulated
pathological form of synaptic plasticity may occur in the
diﬀerent territories of the striatum. It has been reported
in MPTP-treated monkeys that LID involved not only the
sensorimotor part of the striatum, but also its associative
and limbic territories [139]. Third, as noted above, 5-HT
processes could be involved as well [122, 140], particularly in
considering that the “coherent” 5-HT transmission is altered
by L-DOPA [24]. As for DA transmission, alteration in 5-
HT transmission occurring elsewhere than the sensorimotor
part of the striatum may promote abnormal movements in
rodents [122, 141].
In a therapeutic point of view, one possibility is to limit
theexcessiveDAtransmissionbyadministeringaneuroleptic
at risk of generating Parkinsonism. Nevertheless, the atypical
neuroleptic clozapine has been shown to limit dyskinesia
without aggravating the motor score [117]. It is diﬃcult
to interpret the origin of its eﬃcacy as clozapine or other
atypical antipsychotic drugs may slightly block subcortical
DAtransmissionandenhancecorticalDAtransmission[142,
143]. Similar eﬀects could account for the proposed eﬃcacy
of the antipsychotic and partial DA agonist drug aripiprazole
[144]. According to the hypothesis above, treatment that is
enhancing DA transmission in the cortex, that would limit
the impact of cortico-subcortical glutamate transmission
[145], could be a focus of future strategy against LIDs. It is
noticeable that blockers of the N-methyl-d-aspartate recep-
tor such as amantadine can also limit LIDs in patients [146].
The direct control of striatal DA transmission via 5-HT
drugs is diﬃcult to manage because the biochemical and
behavioral relationships between 5-HT receptors and DA
transmission are not well understood [147]. The use of 5-
HT drugs able to control 5-HT nerve activity, to control the
outputofDAfrom5-HTneurons,isagreatopportunity,and
clinical trials are currently underwent to alleviate LIDs using
this strategy. The limit of this approach is that 5-HT drugs
used may also act directly on cells other than 5-HT neurons
due to the widespread distribution of 5-HT receptors in the
brain. Also, a general decrease in DA release from 5-HT neu-
rons may counteract dyskinesia and aggravate Parkinsonism
[148–153]. Again, 5-HT drugs could be used to reinforce
the initial imbalance created by L-DOPA, namely, the quite
homogeneous pattern of DA release induced by L-DOPA,
through cortical mechanisms.
5. Conclusion
Theconsiderationofthe5-HTsysteminthecoremechanism
of action of L-DOPA opens many opportunities to better
apprehendLIDsandtoproposediversetherapeuticstrategies
in the treatment of LIDs. The excess of striatal DA released
by L-DOPA remains an important preoccupation, but the
possibilitytofacilitateDAtransmissioninthecortexcouldbe
also an interesting strategy. Additional studies are warranted
to further study the imbalance of DA transmission promoted
by the intervention of 5-HT neurons in the mechanism of
action of L-DOPA to propose additional brain targets.Parkinson’s Disease 11
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